Clinical Trial Update: Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating whether Vitamin K can reduce redness at injection sites in participants with relapsing-remitting multiple sclerosis treated wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Plegridy (Peginterferon beta-1a)
• Vitamin K (Vitamin K)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 4 | Status: COMPLETED